
Press Release|Articles|January 7, 2025
Camber Pharmaceuticals Announces Addition of Bortezomib for Injection
Listen
0:00 / 0:00
Key Takeaways
- Bortezomib for Injection is a proteasome inhibitor for treating multiple myeloma and mantle cell lymphoma in adults.
- The medication is available in a 3.5 mg strength, packaged in a single-dose vial.
Bortezomib for Injection is a proteasome inhibitor indicated for treatment of adult patients with multiple myeloma and treatment of adult patients with mantle cell lymphoma.
Advertisement
Camber Pharmaceuticals is excited to announce the addition of Bortezomib for Injection.
Bortezomib for Injection is a proteasome inhibitor indicated for:
- treatment of adult patients with multiple myeloma
- treatment of adult patients with mantle cell lymphoma
Bortezomib for Injection is available in 3.5 mg strength, packaged in a single-dose vial.
To find out more information on Bortezomib for Injection please visit:
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
The Peptide Reclassification Everyone's Talking About: A Pharmacist's Take on What RFK Jr's Announcement Actually Means
2
ADA 2026: Earlier GLP-1 and SGLT-2 Use Recommended From Diabetes Diagnosis, Expert Says
3
Brain Inflammation May Not Drive Persistent Long COVID Symptoms, New Imaging Study Finds
4
ADA 2026: Semaglutide Add-On Reduces Glycemic Burden, Cardiometabolic Risk in Older Adults With T2D
5




































































































































